Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

202355 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 34, Issue 10, pp. 885-898

Field-Weighted Citation Impact: 12.60